Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

1 treatments under study, led by Tiratricol

Research Leaders

5 sponsors active, led by Rare Thyroid Therapeutics International AB

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

0.0%

0 terminated out of 3 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

33%

1 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

2Total
Phase 2 (1)
Phase 3 (1)

Trial Status

Completed2
Active Not Recruiting1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 2 completed trials

Clinical Trials (3)

Showing 3 of 3 trials
NCT05579327Phase 3Completed

Withdrawal of Tiratricol Treatment in Males With Monocarboxylate Transporter 8 Deficiency (MCT8 Deficiency)

NCT02396459Phase 2Active Not Recruiting

Triac Trial II in MCT8 Deficiency Patients

NCT06060197CompletedPrimary

MCT8 Deficiency Caregiver Study

Showing all 3 trials

Research Network

Common Treatments

  • Tiratricol2

Active Sponsors

  • Rare Thyroid Therapeutics International AB3
  • Erasmus Medical Center1
  • Premier Research1
  • Vitaccess Ltd1
  • Egetis Therapeutics AB (publ)1

Top Investigators

Related Conditions

  • Allanherndondudley Syndrome3
  • Monocarboxylate Transporter 8 Deficiency1

Activity Timeline